



Antibiotics – Inhaled aztreonam (CAYSTON®)

WA.PHAR.31 Antibiotics Inhaled Aztreonam (CAYSTON)

Related medical policies:

- Antibiotics – Inhaled aminoglycosides

Medical necessity

| Drug | Medical Necessity |
|----------------------|---|
| aztreonam (CAYSTON®) | Cayston® may be considered medically necessary when: Used to treat patients with cystic fibrosis (CF) known to have <i>Pseudomonas aeruginosa</i> in the lungs |

Clinical policy:

| Drug | Clinical Criteria (Initial Approval) |
|----------------------|---|
| aztreonam (CAYSTON®) | <p>Cayston® may be covered when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of cystic fibrosis (CF) 2. Positive culture for <i>Pseudomonas aeruginosa</i> infection in the lungs 3. NONE of the following: <ol style="list-style-type: none"> a. Less than (<) 7 years of age b. FEV₁ less than (<) 25% or greater than (>) 75% predicted c. Positive colonization with <i>Burkholderia cepacia</i> <p>Approve for 12 months</p> |
| | Criteria (Reauthorization) |
| | <p>Documentation of positive clinical response</p> <p>Approve for 12 months</p> |

Dosage and quantity limits

| Drug Name | Dose and Quantity Limits |
|----------------------|-------------------------------|
| Aztreonam (CAYSTON®) | 84mL (56 ampules) per 28-days |

References

1. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. [cited 2016 Dec 19]. Available: <https://www.guideline.gov>.
2. Cayston [package insert]. Foster City, CA: Gilead Sciences Inc; 2014.